It may be April Foolâ€™s Day, but we have chosen to stick to the facts. A recent publication in Molecular Oncology by researchers at the Helmholtz Center in Munich, Germany is the latest to use InSphero GravityPLUSâ„¢ technology to pursue novel breast cancer therapies in 3D spheroids.
Learn more in our magnificent April Newsletter, you won't believe it's not a joke.
Tumor Spheroids Reveal Clues to Targeting Invasive Breast Cancers
Researchers Natalie Falkenberg and NataÅ¡a Anastasov of the Helmholtz Zentrum MÃ¼nchen published results recently in the journal Molecular Oncology, identifying a novel therapeutic strategy for the treatment of breast cancers co-overexpressing HER2 and the protein tyrosine kinase 6 (PTK6). Find the abstract here. Dr. Anastasov is no stranger to the benefits of GravityPLUSâ„¢ technology, having recently contributed an application note describing RNAi-mediated sensitization of breast cancer cells to our library. The Helmholtz duo will be presenting recent work in two posters at the 2015 AACR Annual Meeting in Philadelphia, PA later this month.
InSphero Nominated as Finalist for 2015 Export Award
Export is the backbone of the Swiss economy, with approximately 12% of Swiss companies working in the export business. Our patented shipping process allows us to deliver assay-ready microtissues at 37Â°C to our customers around the world, and earned us one of 3 finalist nominations for the 2015 Export Award, considered the "Oscar" of the Swiss export industry. Winners will be announced at the Forum for Swiss Foreign Trade in Zurich on 23 April.
Learn more and hold your thumbs (or cross your fingers in the US) for us!
3D InSightâ„¢ Toxicology Services
Let our 3D experts make hepatotoxicity and embryotoxicity testing simple and more relevant with standard services utilizing our 3D InSightâ„¢ microtissues:
Wednesday, March 26th marked 6 years since the founding of InSphero. We celebrate with a review of the top innovations from our first 6 years. What will year 7 have to offer? Here's a hint...you won't have to wait long to find out.